CrossLife Technologies Overview
- Year Founded
-
2010
- Status
-
Private
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$1000K
- Investors
-
5
CrossLife Technologies General Information
Description
Developer of molecular diagnostics technologies designed to detect infectious and non-communicable diseases. The company's molecular diagnostics technologies are based on nucleic acid and DNA and it develops technologies into pathogen detection tests for many infectious diseases including HIV, malaria, chikungunya, and flu, enabling doctors to detect infectious pathogens directly from diverse sample types without sample preparation, polymerase chain reaction or instrumentation.
Contact Information
Website
www.crosslifetech.comCorporate Office
- 5937 Darwin Court
- Suite 105
- Carlsbad, CA 92008
- United States
Corporate Office
- 5937 Darwin Court
- Suite 105
- Carlsbad, CA 92008
- United States
CrossLife Technologies Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
9. Grant | 15-Jan-2021 | $1000K | Completed | Startup | ||
8. Grant | 15-Sep-2019 | 00000 | Completed | Startup | ||
7. Grant | 12-Sep-2019 | 00000 | Completed | Startup | ||
6. Grant | 15-Mar-2019 | 000000 | Completed | Startup | ||
5. Grant | 01-Jan-2018 | 00000 | Completed | Startup | ||
4. Grant | 01-Jan-2017 | 00000 | Completed | Startup | ||
3. Grant | 01-Jul-2016 | 00000 | Completed | Startup | ||
2. Grant | 10-Mar-2016 | $2.43M | Completed | Startup | ||
1. Accelerator/Incubator | Completed | Startup |
CrossLife Technologies Patents
CrossLife Technologies Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20210139958-A1 | Engineered gyri-like mutein aptamers, and related methods | Pending | 13-Nov-2019 | 0000000000 | |
EP-4058580-A1 | Engineered gyri-like mutein aptamers, and related methods | Pending | 13-Nov-2019 | 0000000000 | |
EP-4058580-A4 | Engineered gyri-like mutein aptamers, and related methods | Pending | 13-Nov-2019 | 000000000 | 0 |
US-20200354800-A1 | Rapid nucleic acid detection without sample preparation | Active | 08-May-2019 | 0000000000 | |
US-11685960-B2 | Rapid nucleic acid detection without sample preparation | Active | 08-May-2019 | C12Q1/701 | 0 |
CrossLife Technologies Executive Team (1)
Name | Title | Board Seat |
---|---|---|
Hyundae Cho Ph.D | Founder, President, Chief Executive Officer & Board Member |
CrossLife Technologies Investors (5)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
National Science Foundation | Government | 000 0000 | 000000 0 | |
National Institute for Allergy and Infectious Disease | Government | 000 0000 | 000000 0 | |
National Institutes of Health | Government | 000 0000 | 000000 0 | |
U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 | |
Bio, Tech and Beyond | Accelerator/Incubator | 000 0000 | 000000 0 |
CrossLife Technologies FAQs
-
When was CrossLife Technologies founded?
CrossLife Technologies was founded in 2010.
-
Who is the founder of CrossLife Technologies?
Hyundae Cho Ph.D is the founder of CrossLife Technologies.
-
Who is the CEO of CrossLife Technologies?
Hyundae Cho Ph.D is the CEO of CrossLife Technologies.
-
Where is CrossLife Technologies headquartered?
CrossLife Technologies is headquartered in Carlsbad, CA.
-
What industry is CrossLife Technologies in?
CrossLife Technologies’s primary industry is Medical Supplies.
-
Is CrossLife Technologies a private or public company?
CrossLife Technologies is a Private company.
-
What is CrossLife Technologies’s current revenue?
The current revenue for CrossLife Technologies is 000000.
-
Who are CrossLife Technologies’s investors?
National Science Foundation, National Institute for Allergy and Infectious Disease, National Institutes of Health, U.S. Department of Health and Human Services, and Bio, Tech and Beyond have invested in CrossLife Technologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »